Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cellular Biomedicine's Stock Price Quadruples in Two Months

publication date: Aug 15, 2014
On Monday, August 18, Dr. William Cao, CEO of Cellular Biomedicine Group will ring the closing bell at NASDAQ to celebrate CBMG's recent listing on the exchange.  CBMG is a US-headquartered biotech that is developing new treatments for degenerative diseases and cancer in China. The NASDAQ event caps a busy two months for CBMG. During that time, the company reported positive data from a trial of its knee arthritis treatment, jettisoned its consulting business, raised $10 million in a private placement, paid $23 million to acquire a China cellular products company – and the company's stock price rose from below $6 to $23. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital